The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
177Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community setting.
 
Jessica Sassic
No Relationships to Disclose
 
Sadaf Farasat
No Relationships to Disclose
 
David Hermel
No Relationships to Disclose
 
Darren Sigal
Leadership - Celularity
Stock and Other Ownership Interests - Celularity; Karyopharm Therapeutics; Lisata Therapeutics
Honoraria - Ipsen
Consulting or Advisory Role - Celularity; Lisata Therapeutics
Speakers' Bureau - Ipsen
Research Funding - Abivax; ARIAD/Incyte; OBI Pharma
Patents, Royalties, Other Intellectual Property - Patent on "a method for treating neuroendocrine tumors" using TRK inhibitors.
 
Marin Feldman Xavier
Honoraria - Abbvie; Acrotech Biopharma; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Genentech; Genmab; Lilly O.; MorphoSys; MorphoSys/Incyte; Pharmacyclics; Stemline Therapeutics
Consulting or Advisory Role - Abbvie; Acrotech Biopharma; AstraZeneca; Celgene; E.R. Squibb Sons, LLC; Incyte; Janssen; Kite, a Gilead Company; TG Therapeutics
Travel, Accommodations, Expenses - Abbvie